Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

NCT06751524 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer (CRC)
Pancreatic Cancer
Non-Small Cell Lung Cancer (NSCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Sarcoma
Ovarian Cancer
Prostate Cancer

Interventions

DRUG: Botensilimab
DRUG: Balstililmab

Sponsor

Agenus Inc.